27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Myriad Genetics, Inc. (Nasdaq: MYGN) revealed that its board has approved an additional $200 million authorization for its share buyback program. According to the company, as of the end of the third quarter of fiscal year 2016, it bought back higher than $1.1 billion of stock since the inception of the program in 2010 at an average share price of $26.16.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Myriad CFO, Bryan Riggsbee, said, "Our priorities for capital deployment remain the same, first, internal research and development, followed by acquisitions, and lastly, share repurchases. We will continue to opportunistically repurchase shares at valuation thresholds that we believe do not reflect the inherent value of the Company and as we look to deploy our capital most effectively to maximize shareholder returns over the long-term."
The company indicated its share buyback program were made through open market or privately negotiated purchases as determined by its management. The amount and timing of stock repurchases would depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.